Skip to content
OpenCapital
Get started

Eli Lilly LLY Neuroscience — Revenue

Other product segments

Mounjaro
$8.66B+125%
Zepbound
$4.16B+79.9%
Verzenio
$1.3B+12.3%
Jardiance
$1.11B+9.9%
Other oncology
$966M+22.4%
Trulicity
$919M-16.1%
Other cardiometabolic health
$905M-4.2%
Taltz
$733M-3.8%
Other immunology
$470M+44.2%

Similar metrics at other companies

Medtronic logo
MDTNeuroscience — Net Sales
$2.75B+5.0%
AbbVie logo
ABBVOther Neuroscience — Net revenues
$125M-19.4%
Johnson & Johnson logo
JNJOTHERNEUROSCIENCE — Sales to customers (Note 9)
$262M-5.4%
Lantheus Holdings logo
LNTHNeurology — Revenue
$35.44M—
Amneal Pharmaceuticals, Inc. logo
AMRXCentral nervous system — Net revenue
$83.38M+23.3%
IAR
IARTNeurosurgery — Total Revenues
$198.2M+3.8%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's neuroscience — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's neuroscience — revenue?
Eli Lilly (LLY) reported neuroscience — revenue of $382M in Q1 2026.
How has Eli Lilly's neuroscience — revenue changed year-over-year?
Eli Lilly's neuroscience — revenue increased by 40.4% year-over-year, from $272M to $382M.
What is the long-term trend for Eli Lilly's neuroscience — revenue?
Over 4 years (2021 to 2025), Eli Lilly's neuroscience — revenue has grown at a -7.5% compound annual growth rate (CAGR), from $1.9B to $1.39B.
What does neuroscience — revenue mean?
This metric represents the total net sales generated from pharmaceutical products specifically categorized under the neuroscience therapeutic area. It reflects the market demand and commercial success of treatments targeting neurological conditions, such as Alzheimer's disease or other central nervous system disorders. This revenue stream is a critical indicator of the company's ability to monetize its specialized R&D pipeline within this specific medical vertical.